A Study of the Effectiveness of Moderna COVID-19 Vaccine

Last updated: April 30, 2024
Sponsor: ModernaTX, Inc.
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Covid-19

Sars-cov-2

Treatment

mRNA-1273

Clinical Study ID

NCT05933304
mRNA-1273-P901
  • Ages > 6
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is an observational cohort study to evaluate real-world vaccine effectiveness and durability of Moderna COVID-19 vaccine among a diverse population at Kaiser Permanente Southern California (KPSC).

The primary objective of this study is to evaluate the vaccine effectiveness (VE) of receipt of Moderna COVID-19 vaccine in preventing SARS-CoV-2 infection and severe COVID-19 disease.

SARS-CoV-2 infection will be defined as a positive antigen test result as well as a positive molecular diagnostic test among symptomatic or asymptomatic participants or a COVID-19 diagnosis code. Severe COVID-19 disease will be defined as COVID-19 hospitalization or mortality.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged ≥18 years at index date (participants aged 6 months through 17 years will also beincluded after Food and Drug Administration [FDA] authorization to vaccinate youngerage groups)
  • KPSC member for ≥12 months prior to index date through 14 days after the index date (allowing a 31-day gap)

Exclusion

Exclusion Criteria:

  • Receipt of a COVID-19 vaccine other than Moderna COVID-19 vaccine prior to or on theindex date
  • Receipt of 2 doses of Moderna COVID-19 vaccine <24 days apart for 2-dose exposedcohort
  • Receipt of any COVID-19 vaccine <14 days after the index date
  • No health care utilization and no vaccination from the 2 years prior to the index datethrough the index date
  • Occurrence of a COVID-19 outcome <14 days after the index date

Study Design

Total Participants: 1000000
Treatment Group(s): 1
Primary Treatment: mRNA-1273
Phase:
Study Start date:
December 18, 2020
Estimated Completion Date:
April 14, 2025

Study Description

This study utilized electronic healthcare data collected within the Kaiser Permanente Southern California (KPSC) integrated healthcare system which provides care to over 4.6 million individuals. Participants in this study received vaccination and were assessed for study outcomes as part of routine care. Vaccination information and study outcome status was assessed using procedure, diagnostic, and laboratory code information. Medical chart review was conducted to assess the association of severe outcomes (hospitalization and death) with COVID-19 illness.

Analyses assessing absolute vaccine effectiveness will identify participants who receive Moderna COVID vaccine from the KPSC electronic healthcare database and match them to unvaccinated participants based on age, sex, race/ethnicity, and data of vaccination (index date). Vaccinated and unvaccinated participants will then be followed-up in the database for the occurrence of study outcomes. Cox proportional hazards regression will be used to compare the relative risk of study outcomes by vaccination status.

Analyses of relative vaccine effectiveness will identify participants who receive specific dose number and formulation of Moderna COVID vaccine (Group N) from the KPSC electronic healthcare database and match them to a group of vaccinated participants with a different dose/formulation type (i.e. Group n-1). Similar matching criteria will be applied. Both groups will be followed for study outcomes and cox proportional hazards regression will be used to compare the relative risk of study outcomes by vaccination status.

Connect with a study center

  • Kaiser Permanente Southern California

    Pasadena, California 91101
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.